MSD at BTOG 2022

MSD promotional satellite symposium at BTOG Annual Conference 2022

MSD is proud to have been the Diamond sponsor of the British Thoracic Oncology Group (BTOG) in 2022

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Living with lung cancer: A patient and clinical perspective

The recording of our sponsored satellite symposium with Dr Petra Jankowska and Clinical Nurse Specialist Lucy Ford is now available to watch below.

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA® (pembrolizumab) plus chemotherapy for squamous patients has been reimbursed in England since August 2019.1 Dr Jankowska and Lucy Ford present a case study of a PD-L1 1% squamous mNSCLC patient who completed 2 years on KEYNOTE-407 in August 2021.

They provide first-hand clinical experience, as well as patient feedback, of the various phases of treatment (i.e. starting treatment, transitioning onto maintenance and completing treatment at 2 years) including how they structured services to support their patient through these stages.


If you would like to virtually connect with an MSD representative, please email us to set up an appointment:

For more information about KEYTRUDA in NSCLC:


  1. NHS England. National Cancer Drugs Fund List – Version 1.209. 2022.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website